Opportunities and Challenges in Developing a Cryptosporidium Controlled Human Infection Model for Testing Antiparasitic Agents

Rajiv S. Jumani,† Johanne Blais,† Hanns-Christian Tillmann, Florencia Segal, Dean Wetty, Christian Ostermeier, Natko Nuber, Jay Lakshman, Natasha Aziz, Richa Chandra, Wilbur H. Chen, Cynthia L. Chappell, Thierry T. Diagana, and Ujjini H. Manjunatha*

ABSTRACT: Cryptosporidiosis is a leading cause of moderate-to-severe diarrhea in low- and middle-income countries, responsible for high mortality in children younger than two years of age, and it is also strongly associated with childhood malnutrition and growth stunting. There is no vaccine for cryptosporidiosis and existing therapeutic options are suboptimal to prevent morbidity and mortality in young children. Recently, novel therapeutic agents have been discovered through high-throughput phenotypic and target-based screening strategies, repurposing malaria hits, etc., and these agents have a promising preclinical in vitro and in vivo anti-Cryptosporidium efficacy. One key step in bringing safe and effective new therapies to young vulnerable children is the establishment of some prospect of direct benefit before initiating pediatric clinical studies. A Cryptosporidium controlled human infection model (CHIM) in healthy adult volunteers can be a robust clinical proof of concept model for evaluating novel therapeutics. CHIM could potentially accelerate the development path to pediatric studies by establishing the safety of a proposed pediatric dosing regimen and documenting preliminary efficacy in adults. We present, here, perspectives regarding the opportunities and perceived challenges with the Cryptosporidium human challenge model.

KEYWORDS: diarrhea, cryptosporidiosis, human-challenge model, drug discovery, Cryptosporidium, pediatric development, antiparasitic agent, CHIM

CRYPTOSPORIDIOsis MEDICAL NEED

Cryptosporidium spp. are protozoan parasites responsible for acute enteritis with diarrhea as the primary clinical symptom. Cryptosporidiosis in humans is caused primarily by two species, Cryptosporidium parvum and Cryptosporidium hominis.1 Transmission typically occurs when feces containing Cryptosporidium oocysts from infected animals or humans contaminate food or water supplies, thereby infecting humans predominantly via the fecal oral route. Once ingested, the oocysts reach the small intestine, where motile, infectious sporozoites are released and infect intestinal epithelial cells. The organisms then go through multiple cycles of asexual replication, followed by sexual reproduction, ultimately resulting in excretion of numerous mature oocysts in the feces.2 During a single infection period individuals may shed up to 10⁸−10⁹ oocysts.3

Cryptosporidiosis is a self-limiting infection in immunocompetent adults and can be successfully managed with supportive care and treatment. In the vulnerable patients population (young children and immunocompromised adults), Cryptosporidium infection is associated with prolonged (7–14 days) or persistent (>14 days) diarrhea.4 Indeed, Cryptosporidium spp. are a leading cause of pediatric diarrhea in low- and middle-income countries (LMICs) and represents one of the leading causes of diarrheal deaths in young children aged 0–24 months.1,5–8 Cryptosporidiosis is estimated to be responsible for 48 000–202 000 deaths annually in children younger than two years of age in South Asia and Sub-Saharan Africa and ~7.6 million diarrhea cases annually are attributable to Cryptosporidium infection in these regions.5,9 In addition, evidence suggests that repeated Cryptosporidium infections in children are associated with long-term effects and debilitating growth-stunting.10,11

Nitazoxanide (Alinia) is the only drug approved by the U.S. Food and Drug Administration for the treatment of cryptosporidiosis in children aged 1 year of age and older.

Special Issue: Gut Pathogens

Received: January 31, 2021
Published: April 6, 2021

https://doi.org/10.1021/acsinfecdis.1c00057
ACS Infect. Dis. 2021, 7, 959–968
and immunocompetent adults.\textsuperscript{12,13} It is a safe oral antiparasitic agent and significantly improves clinical response and reduces the duration of diarrhea and oocyst shedding in immunocompetent adults with cryptosporidiosis.\textsuperscript{14,15} As a parasitostatic agent,\textsuperscript{16} efficacy of nitazoxanide is largely dependent on host-immunity and is not effective for treating cryptosporidiosis in immunocompromised patients.\textsuperscript{17,18} In a study that enrolled HIV-negative, malnourished children, nitazoxanide treatment resulted in resolution of diarrhea in only 56% of children (23% in placebo group) and only 52% demonstrated oocyst clearance (14% in placebo group).\textsuperscript{19} The limited efficacy of nitazoxanide in malnourished children may be attributed to immunological alterations or intestinal dysbiosis associated with malnutrition in these children.\textsuperscript{20,21} Overall, there is a pressing, highly unmet therapeutic need to address enteric cryptosporidiosis in three major target patient populations: young children aged 0–24 months in LMICs, malnourished children under age five, and immunosuppressed individuals of any age.

\section*{ANTI-CRYPTOSPORIDIUM DRUG DISCOVERY AND DEVELOPMENT EFFORTS}

Despite the substantial global disease burden and a clear need for effective antiparasitic treatments, cryptosporidiosis remains an under-appreciated global health concern. Earlier efforts to repurpose approved drugs, such as paromomycin, rifaximin, spiramycin, azithromycin, teixobactin, HIV protease inhibitors, or clofazimine, for the treatment of cryptosporidiosis in HIV/AIDS patients have been unsuccessful.\textsuperscript{22,23} Recently, significant progress has been made in identifying and optimizing diverse new chemical entities (NCEs) with promising in vitro activity and in vivo efficacy as defined in the proposed target product profile for cryptosporidiosis treatment.\textsuperscript{24,25} Some of the promising NCEs include \textit{Cryptosporidium} calcium-dependent protein kinase 1 (CpCDPK1) inhibitors,\textsuperscript{26} phosphatidylinositol-4-OH kinase (PI(4)K) inhibitors,\textsuperscript{27} bicyclic azetidines that are phenylalanyl-tRNA synthetase inhibitors,\textsuperscript{28} methionyl-tRNA synthetase inhibitors,\textsuperscript{29,30} a choline-based phospholipid VB-201,\textsuperscript{31} and multiple novel cell-active hits.\textsuperscript{32} Most of these NCEs have demonstrated antiparasitic activity against both \textit{C. parvum} and \textit{C. hominis}. Further, unlike nitazoxanide, many of these anti-\textit{Cryptosporidium} NCEs are effective in reducing the fecal oocyst burden in immunocompromised mouse models. This rich and diverse pipeline of drug candidates is very encouraging and could also enable drug combinations to address the potential for drug resistance.\textsuperscript{33}

To address the unmet medical need in the highly vulnerable young pediatric cryptosporidiosis patient population, the most critical aspects are an exceptional safety profile and robust efficacy demonstrated by rapid resolution of diarrhea to minimize the risk of dehydration. A few candidate molecules such as the CDPK inhibitor BKI-1369,\textsuperscript{32} PI(4)K inhibitor KDU731,\textsuperscript{33} MMV6659917,\textsuperscript{16} and 6-carboxamide benzoxaborole AN7973\textsuperscript{34} have demonstrated promising activity in resolving diarrheal symptoms in neonatal calves, a preclinical model of cryptosporidiosis diarrhea which closely resemble pediatric infection and illness. Overall, in the past few years, substantial progress has been made in identifying diverse NCEs, and it is anticipated that some may soon start clinical development.

\section*{CHALLENGES IN DEVELOPING A NOVEL ANTIPARASITIC AGENT TO TREAT PEDIATRIC CRYPTOSPORIDIOSIS}

Cryptosporidiosis disproportionately affects young children, and the highest unmet medical need is in the malnourished who are at the greatest risk for severe disease and mortality.\textsuperscript{22} Drug development is expensive, takes considerable time, has a high attrition rate and the pediatric population in LMICs presents additional challenges. Four study populations to establish proof of concept (PoC) of new anti-\textit{Cryptosporidium}

\begin{table}[h]
\centering
\caption{Pros and Cons of Potential First in Human Proof of Concept Efficacy Studies for Testing a Novel Anti-\textit{Cryptosporidium} NCEs}
\begin{tabular}{|l|l|l|}
\hline
\textbf{NCE Target} & \textbf{Pros} & \textbf{Cons} \\
\hline
\textit{Cryptosporidium} controlled human infection model (CHIM) in healthy adults & - prospect of benefit in healthy adults with \textit{Cryptosporidium} induced diarrhea & - \textit{C. parvum} model utilized for technical reasons, although \textit{C. hominis} more common human pathogen \\
& - informs dose selection for studies in pediatric patients & - needs to be established and validated \\
& - clinical syndrome, parasitological and clinical end points under mono-infection condition & - limited viability period of GMP oocysts \\
& - conducted in healthy volunteers, mitigates safety confounders & - monoinfection state may not be clinically relevant to target pediatric patient population \\
& - phase 1 settings: faster recruitment and smaller sample size & - unknown translatability of efficacy to target population \\
\hline
Adult HIV-positive cryptosporidiosis patients & - natural infection in potential secondary target population & - confounded safety and efficacy due to advanced immunocompromised state \\
& - PK in context of high GI motility & - presence of other pathogens/coinfections and/or concurrent medications \\
\hline
Pediatric cryptosporidiosis patient population & - assessment of safety and efficacy in the target population & - high mortality \\
& - natural course of infection & - operational complexity in the resource poor settings \\
& - with relevant clinical strains & - prospect of clinical benefit will not have been previously established \\
\hline
\end{tabular}
\end{table}
Table 2. Summary of the Published Cryptosporidium CHIM Studies

| species isolate | study reference | dose          | N    | infection* (%) | illness* (%) | notes |
|-----------------|-----------------|---------------|------|----------------|--------------|-------|
| C. parvum Iowa  | DuPont, NEJM 1995 | $3 \times 10^0$–$10^9$ | 29   | 20–100         | 0–38         | · first Cryptosporidium human challenge study; ID$_{50}$ established 132 oocysts | · oocyst purified from neonatal calves | · self-limited infection and illness observed; at dose $\geq 1000$ oocysts: 100% infection, 71% enteric symptoms and 29% diarrheal illness observed |
| C. parvum Iowa  | Okhuysen, Inf Imm 1998 | $5 \times 10^5$ | 19   | 84             | 58           | · rechallenge (extension of DuPont 1995) study in healthy adults | · fewer subjects shed oocysts after the second exposure (16%) than after the first exposure (63%) | · lower "intensity of diarrhea" with rechallenge |
| C. parvum Iowa  | Chappell, AJTMH 1999 | $5 \times 10^0$–$5 \times 10^4$ | 17   | 41             | 59           | · infectivity in pre-existing anti-C. parvum serum IgG | · ID$_{50}$ is 1880 oocysts, 20× higher than in seronegative volunteers |
| C. parvum Iowa  | Okhuysen, JID 1999 | $3 \times 10^0$–$10^5$ | 29   | 40–100         | 52           | · virulence of 3 C. parvum isolates compared; Iowa and UCP, originally isolated from calves and passed in calves; whereas TAMU isolated from a student who got infected from foal, also passed in calves | · prior exposure provides protection from infection and illness at low oocyst doses |
| C. parvum UCP   | Okhuysen, CID 1998 | $5 \times 10^0$–$10^4$ | 20   | 44–100         | 56–75        | · ID$_{50}$ for Iowa, UCP, and TAMU established as 87, 1042, and 9 oocysts, respectively, based on presumed infection |
| C. parvum TAMU  | Okhuysen, JID 2002 | $10^0$–$3 \times 10^3$ | 16   | 33–75          | 60–75        | · TAMU isolate induced higher diarrhea rate for a longer duration than Iowa or UCP isolates |
| C. parvum Iowa/TAMU | Alcantara, AJTMH 2003 | $10^0$–$10^3$ | 15   | 50–67          | 33–83        | · importance of intestinal inflammation in C. parvum challenge versus pediatric patients as measured by fecal IL8, lactoferrin, and TNFα | · significantly more inflammation in pediatric Cryptosporidium patients than adult volunteers |
| C. parvum UCP   | Okhuysen, CID 1998 | $10^0$–$10^5$ | 6    | 33–75          | 60–75        | · prophylactic effect of bovine hyperimmune anti-Cryptosporidium colostrum hyperimmune colostrum not protective against infection |
| C. parvum Moreau | Okhuysen, JID 1999 | $10^0$–$3 \times 10^3$ | 20   | 40–100         | 56–75        | · oocysts originally isolated from red deer, passed in sheep and later in calves | · ID$_{50}$ 300 oocysts; diarrheal illness was frequently associated with oocyst excretion |
| Healthy Volunteers Challenged with C. parvum: N = 176 |
| C. hominis TUS02 | Chappell, AJTMH 2006 | $10^0$–$3 \times 10^5$ | 5    | 20–80          | 40–75        | · first C. hominis human challenge study; ID$_{50}$ established 10–83 oocysts | · oocyst purified from gnotobiotic piglets |
| C. meleagris    | Chappell, AJTMH 2011 | $10^5$        | 10   | 100            | 80           | · first C. meleagris human high-dose challenge study | · infection and illness similar to C. parvum challenge studies |
| C. muris        | Chappell, AJTMH 2015 | $10^5$        | 6    | 100            | 33           | · first C. muris human high-dose challenge study | · oocyst purified from Nu/Nu mouse |

"Note: In most studies, "illness" was defined as the passage of 3 unformed stools in 8 h or >3 unformed stools in 24 h accompanied by the presence of one or more enteric symptoms, including fever, nausea, vomiting, abdominal pain or cramps, and gas-related intestinal symptoms. "Infection" was defined as the excretion of oocysts in stool by a direct immunofluorescence assay (DFA) after a flow-through period of 36 h postchallenge."
compounds are possible: (i) adult immunocompromised patients in LMICs; (ii) adult patients during a sporadic outbreaks; (iii) malnourished pediatric patients in endemic regions; and (iv) a Cryptosporidium controlled human infection model (CHIM) in healthy adult volunteers. Typical drug development and regulatory pathways involve demonstrating the prospect of direct benefit in adult populations before initiating pediatric studies.35

Cryptosporidium infection is a common cause of chronic diarrhea in HIV/AIDS patients in LMICs.36 Currently, the best treatment is reconstitution of the immune response via antiretroviral therapy. HIV/AIDS patients are the only naturally occurring adult population of adequate size to facilitate early stage drug efficacy studies for cryptosporidiosis in LMICs. However, a recent controlled clinical trial to assess the safety and efficacy of clofazimine for the treatment of Cryptosporidium parvum high-dose infection model (CHIM) in adult healthy volunteers. Typical drug development and regulatory pathways involve demonstrating the prospect of direct benefit in adult populations before initiating pediatric studies.35

Figure 1. Pediatric cryptosporidiosis drug discovery and development, a proposed path to registration. Development of C. parvum oocyst CHIM is shown above. Cp, C. parvum and Ch, C. hominis.

Figure 2. Proposed controlled human C. parvum high-dose infection model for testing NCE with anticipated incubation period and duration of infection. NTZ, nitazoxanide.

Clinical and microbiological read-outs

| Health Screening & recruitment | Incubation period (2-5 days) | Duration of Crypto infection (3-14 days) | NTZ treatment Day 21 |
|-------------------------------|-----------------------------|----------------------------------------|----------------------|
| NCE for 5-7 days               |                             |                                        | NTZ                  |

■ ESTABLISHING A CRYPTOSPORIDIUM CHIM TO ENABLE DRUG DISCOVERY

More than 15 species of Cryptosporidium are known to cause human infection with two predominant clinical species, C. hominis (~80%) and C. parvum (~10%).9 The safety and feasibility of controlled human Cryptosporidium challenge studies are well documented in the literature, using C. parvum,42–48 C. hominis,39 C. meleagris,50 and C. muris51. These challenge studies focused on: identifying the minimum human infectious dose for C. parvum and C. hominis; comparing the clinical symptoms caused by different clinical isolates; understanding the impact of prior Cryptosporidium infection on rechallenge; assessing fecal inflammatory markers; and exploring mechanisms of pathogenesis (Table 2). To date, more than 200 healthy adult volunteers have been challenged with Cryptosporidium oocysts, of which ~175 were infected with various isolates of C. parvum. Among them, C. parvum Iowa isolate from the University of Arizona was used in 5 of the 7 published studies.45,44,46–48 The C. parvum Iowa isolates used were not from a single oocyst stock, but were
continuously propagated in calves, which could lead to mutations and/or genetic drift in oocysts over time. In these CHIM studies, a high percentage of infections with Cryptosporidium could be elicited and many of the infected individuals developed clinical symptoms after challenge (summarized in Table 2). In addition, no safety concerns (other than clinical symptoms of acute cryptosporidiosis) have been observed in any of the CHIM studies with doses up to $10^6$ oocysts.

We propose establishing a C. parvum Iowa isolate high-dose oocyst human challenge model to enable future assessment of NCEs for the treatment of cryptosporidiosis. The proposed path for pediatric cryptosporidiosis drug discovery and development incorporates CHIM for establishing PoC for efficacy in adults (Figure 1). The synopsis of a CHIM study design is further outlined in Figure 2. Following Cryptosporidium challenge, healthy, immunocompetent individuals may experience profuse, watery, nonbloody diarrhea after an incubation period of 3–12 days. Without any treatment, symptoms are expected to resolve within 2–3 weeks or less (mean duration of 12.7 days) but could persist for up to a month. Thus, to minimize the risk of long-term asymptomatic shedding and/or recurrence, all subjects with elicited infection will receive nitazoxanide treatment, the standard of care, at the end of the 21-day study. Of note, as a precaution any subjects who remain asymptomatic postchallenge will also be treated to prevent any potential secondary transmission. Once CHIM is established, it could potentially be used for a NCE development after phase I studies. The following section highlights the opportunities and challenges with Cryptosporidium CHIM in healthy adult volunteers, a model designed for establishing efficacy with NCEs.

### OPPORTUNITIES AND CHALLENGES IN CRYPTOSPORIDIUM CHIM

Some of the major advantages of Cryptosporidium CHIM are as follows:

- It enables the assessment of the prospect of benefit in adults before NCE is advanced into efficacy studies in the vulnerable pediatric patient population in the LMICs.
- Subjects in a cryptosporidiosis CHIM will have a typical noninflammatory diarrhea because of a single pathogen, allowing for unconfounded interrogation of the effect of an investigational drug on clinical and parasitological end points.
- It allows for careful and extensive analysis of the pharmacokinetic–pharmacodynamic (PK–PD) relationship of an investigational drug in the presence of diarrhea, providing valuable data that informs dose selection for future pediatric clinical trial designs.
- Cryptosporidium challenges induce nonlife threatening, self-limiting infections in healthy adults with the option to use nitazoxanide as the rescue medication.
- Finally, CHIM PoC efficacy studies can help prioritize NCEs for juvenile toxicity studies designed to understand potential adverse effects on postnatal growth and development, thereby hastening the pediatric clinical development.

Overall, Cryptosporidium CHIM may enable scientifically rigorous and rapid clinical development path for novel drug candidates to treat cryptosporidiosis in young children. However, there are some challenges in establishing and utilizing a Cryptosporidium CHIM for drug development. Some of these challenges and mitigation strategies are described below.

**Challenge Organisms Are Regulated As Biological Products and Drugs in the US.** According to a 2013 guidance from the US Food and Drug Administration (FDA), an Investigational New Drug Application (IND) is required for challenge studies in which a live organism is administered to subjects to study the pathogenesis of disease or the host response to the organism. While the challenge organism is not intended to have a therapeutic purpose, there is intent to affect the structure or function of the body. Consequently, the FDA considers the organism to be both a biological product and a drug and therefore subject to the corresponding regulatory requirements. As per the Federal Food, Drug, and Cosmetic Act, current good manufacturing practice (CGMP) must be in effect for the manufacture of investigational drug used during phase 1 clinical trials. C. parvum human challenge studies (Table 2) were conducted in the US during 1990s and early 2000s with oocysts purified from experimentally infected neonatal calves. At the time, there was no requirement for an IND application for the challenge organism. Currently, there is no suitable robust manufacturing process available to produce Cryptosporidium oocysts ex vivo. A major barrier to producing large quantities of oocysts ex vivo has been the lack of a robust and reproducible in vitro culture system, although a hollow fiber continuous culture setup has been described with C. parvum. Our attempts to establish a robust hollow fiber C. parvum in vitro culture system were unsuccessful. The proposed alternate approach is by obtaining a purified C. parvum (Iowa isolate) oocysts from experimentally infected neonatal calves (a non-GLP source, Good Laboratory Practice). Oocysts are, then, surface sanitized, quality tested, and released by a GMP facility for use in the establishment of CHIM. We have also developed a surface sanitization protocol using peracetic acid to inactivate potential microbial and viral contaminants and demonstrated that this process is effective while having limited impact on C. parvum oocyst viability (Jumani et al., unpublished). Cryptosporidium oocysts can withstand peracetic acid treatment in contrast to other organisms. Peracetic acid is one of the most effective organic peroxide broad-spectrum biocide agents. It has been cleared by FDA as a sanitizer for direct food/food contact surfaces and recommended by CDC for the disinfection and sterilization of healthcare facilities and equipment, including reusable medical and dental devices. To confirm the effectiveness of the sanitization procedure, we have tested the oocysts treated with peracetic acid for the presence of microbial contaminants and shown that the sanitized oocysts do not contain any viable aerobic or anaerobic microorganisms as determined by regulatory guidelines. Furthermore, to confirm the effectiveness of the sanitization procedure on viral contaminants, purified oocysts were artificially contaminated with six different types of model viruses. The peracetic acid treatment reduced the infectivity of the spiked viruses to below the limit of detection. Currently, we are evaluating the logistics and feasibility of releasing C. parvum oocysts under GMP for CHIM studies.

**C. parvum Oocysts Gradually Lose Viability with Storage.** Despite being highly resistant to harsh disinfection conditions, reliable cryopreservation of Cryptosporidium oocysts has been a long-standing challenge. A cryopreservation
method for *C. parvum* oocysts has been recently developed, but the scalability and impact of cryopreservation to elicit human infection has not been evaluated. Currently, the routinely used storage condition for *C. parvum* oocysts is in aqueous suspension at 2–8 °C for 4–6 months. As the oocyst suspension ages, the viability reproducibly decreases and thus, the potential to induce an infection also decreases. Consequently, to ensure consistent infectivity in the clinic, CHIM will require a fresh batch of GMP oocysts every few months and may need to adjust the oocyst dose for loss of viability over time.

**Majority of Clinical Infections Are Caused by *C. hominis* and Anthroponotic *C. parvum* Strains.** Epidemiologic studies have revealed that the majority of clinical infections in the endemic countries is caused by *C. hominis* (∼80%) and anthroponotic *C. parvum* (∼10%) isolates. The proposed high-dose oocyst human challenge model uses a *C. parvum* Iowa isolate, a zoonotic species which can cause a profuse watery diarrhea in both cattle and humans. Therefore, effectiveness of NCE in the CHIM may not directly reflect the efficacy against the most predominant clinical species. Though *C. parvum* and *C. hominis* share ∼96% nucleotide identity, it is critical to make sure the molecular target is conserved across *Cryptosporidium* species and determine the activity of NCE against *C. hominis* in early preclinical drug discovery stages. Several promising NCEs have been reported to have similar potency against *C. parvum* and *C. hominis* in vitro suggesting the molecular target is conserved across these two species.

**No Clear Relationship between the *C. parvum* Oocyst Infective Dose and Clinical Illness in Healthy Adults Has Been Established.** The *C. parvum* Iowa isolate human challenge studies described in the literature have demonstrated that this isolate is capable of inducing infection in up to 100% of healthy volunteers with adequate doses of oocysts, but not all infected volunteers will develop diarrhea or other gastrointestinal (GI) symptoms (Table 2). In one study, 100% of healthy volunteers (n = 7) receiving ≥1000 *C. parvum* oocysts, that is, approximately 10 times above ID$_{50}$ (infective dose) developed infection as measured by fecal oocyst shedding; 71% had enteric symptoms, but of these only 29% had diarrhea illness. The absence of a clear relationship between infective dose and diarrhea illness in healthy adults poses a challenge for using CHIM to demonstrate efficacy in improving diarrheal syndrome. It is likely that the positive health status of CHIM participants contributes to this variability. Multiple factors contribute to the susceptibility of the host to clinical manifestations such as host immune status, gut health, GI microbiota, the virulence of the *C. parvum* isolate and prior exposure to *Cryptosporidium*. Our proposed strategy is to use a high oocyst dose to increase the probability of infection and clinical symptoms in CHIM participants. We anticipate that ideally robust parasitological infection will be observed. However, to test efficacy of NCE, sufficient and consistent clinical illness along with parasitological infection in a significant proportion of healthy adults may be needed.

**Risk/Benefit Consideration for Participants.** Aside from a long-term philanthropic contribution to the development of novel therapies for cryptosporidiosis, there is no direct benefit expected for healthy adults participating in a CHIM study. The risks to healthy participants may include GI cryptosporidiosis with mild to severe diarrhea, asymptomatic infections, persistent or recurrent illness, and possible secondary transmission. Extraintestinal manifestations in immunocompetent healthy adults have not been described in the published *Cryptosporidium* human challenge studies. Both symptomatic and asymptomatic infections may result in secondary transmission to household members and other contacts. Overall, the risks to participants and their contacts can be appropriately addressed in a clinical trial protocol for a CHIM study. In comparison, in longitudinal studies of adult outbreak-associated cryptosporidiosis, medium to long-term sequelae after resolution of the acute infection included diarrhea, abdominal pain, nausea, fatigue, headache, and joint pain. These long-term sequelae were more prevalent following infection with *C. hominis* than *C. parvum*. The impact of nitazoxanide treatment on long-term sequelae is unknown. In general, the interpretation of self-reported data from outbreak-associated cohorts requires caution given the potential for bias toward those most adversely affected and those who attributed postacute symptoms to acute cryptosporidiosis. Further, no such long-term sequelae have been described in the published *C. parvum* CHIM studies (Table 2). However, long-term follow up beyond 6–8 weeks was not conducted in most of these studies, but can be potentially monitored in future CHIM studies. Recently, an association between *Cryptosporidium* infections and GI cancers have been proposed, but a causal relationship has not been established. In a 2015, *C. muris* challenge study, two subjects with persistent oocyst shedding were successfully treated with nitazoxanide at 200 mg twice a day for 3 days, and the infection was resolved in both subjects, demonstrating the potential of nitazoxanide as a rescue drug. We propose to administer nitazoxanide to all participants in whom infection was elicited at the conclusion of the study or earlier in case of persistent or severe diarrhea to eliminate any remaining infection and decrease potential long-term risks.

**Uncertain Translatability of NCE Efficacy in a CHIM to Pediatric Cryptosporidiosis Diarrhea.** In immunocompetent adults, *Cryptosporidium* infection causes self-limiting GI illness and symptoms most often completely self-resolve within 1–2 weeks (Table 2). In contrast, *Cryptosporidium* infection in young children, especially the malnourished or otherwise immunocompromised, is associated with life-threatening diarrhea with severe morbidity and mortality. In this vulnerable patient population, *Cryptosporidium* infection is often associated with persistent diarrhea (>14 days) leading to a significant adverse effect on linear (height) growth and nutritional shortfalls. Young children with cryptosporidiosis have more severe inflammation as measured by fecal lactoferrin levels as compared to adult volunteers. This may be due to various factors, including more severe diarrheal illness in children than healthy adults, presence of other enteric pathogens, nutritional status, gut health, sensitivity to fluid loss, and also differences in the virulence of *Cryptosporidium* isolates. Overall, cryptosporidiosis induced experimentally in healthy adults is not the same as the disease observed in the pediatric patients especially with respect to host health status, severity of diarrheal illness and complexity of pathogenesis. However, since the human challenge model recapitulates logarithmic parasite replication in the GI tract leading to fecal oocyst shedding, acute watery diarrhea, and other GI symptoms similar to pediatric patients, the CHIM is a scientifically robust and efficient approach to assess promising antiparasitic agents.
SUMMARY

Cryptosporidium is the second leading cause of diarrhea in young children and a major contributor for diarrheal deaths in LMICs. While cryptosporidiosis disproportionately affects young children, establishment of an adult CHIM is a scientifically robust and efficient way to assess novel antiparasitic agents with relatively less safety risk. Following a standard phase 1 with NCE in healthy adults, the Cryptosporidium CHIM would be a stepping stone to pediatric trials. It should help establishing a prospect of benefit for NCEs in healthy adults before advancing to the vulnerable pediatric population; derisking investment in juvenile toxicology studies; and providing PK/PD data to inform dose selection for pediatric trials.

Three key safety pillars of the proposed C. parvum CHIM studies protect participating healthy adults. First, a GMP-compliant oocyst manufacturing process to be established with sanitization, testing and batch release of oocysts as an investigational medical product. Second, the safety experience from several published CHIM studies. And finally, C. parvum infection in healthy adults causes a self-limiting illness and an effective rescue medication is available. A Cryptosporidium CHIM has the potential to accelerate the development of both new therapeutics and vaccines against cryptosporidiosis. The recent accomplishments in early drug discovery and availability of a Cryptosporidium controlled human infection model offer a compelling vision toward enabling a much-needed parasite-specific treatment for young children suffering from the debilitating effects of cryptosporidiosis.

AUTHOR INFORMATION

Corresponding Author
Ujjini H. Manjunatha — Novartis Institute for Tropical Diseases, Novartis Institutes for BioMedical Research, Inc., Emeryville, California 94608-2916, United States; orcid.org/0000-0002-7461-9303; Email: manjunatha.ujjini@novartis.com

Authors
Rajiv S. Jumani — Novartis Institute for Tropical Diseases, Novartis Institutes for BioMedical Research, Inc., Emeryville, California 94608-2916, United States
Johanne Blais — Novartis Institute for Tropical Diseases, Novartis Institutes for BioMedical Research, Inc., Emeryville, California 94608-2916, United States
Hanns-Christian Tillmann — Novartis Institutes for BioMedical Research, Inc., Translational Medicine, 4056 Basel, Switzerland
Florencia Segal — Novartis Institutes for BioMedical Research, Inc., Cambridge, Massachusetts 02139-4133, United States
Dean Wetty — Novartis Institutes for BioMedical Research, Inc., Cambridge, Massachusetts 02139-4133, United States
Christian Ostermeier — Novartis Pharma AG, 4002 Basel, Switzerland
Natko Nuber — Novartis Pharma AG, 4002 Basel, Switzerland
Jay Lakshman — Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936, United States
Natasha Aziz — Novartis Institute for Tropical Diseases, Novartis Institutes for BioMedical Research, Inc., Emeryville, California 94608-2916, United States
Richa Chandra — Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936, United States

ACKNOWLEDGMENTS

We would like to thank Gu Feng, Jean Messina, Juana Potts, Megan Osborn, Joe Young, Xiaojun Zhao, and other colleagues from Novartis for their support and Deborah Schaefer and Michael Biggs from the University of Arizona and Christopher Huston from the University of Vermont for advice. This work in part supported by Novartis and the Wellcome Trust (Project Number: 219639/Z/19/Z). The funders had no role in study design, data collection, and analysis, decision to publish, or preparation of the manuscript.

REFERENCES

(1) Checkley, W., White, A. C., Jaganath, D., Arrowood, M. J., Calmers, R. M., Chen, X. M., Fayer, R., Griffiths, J. K., Guerra, R. L., Hedstrom, L., Huston, C. D., Kotloff, K. L., Kang, G., Mead, J. R., Miller, M., Petri, W. A., Priest, J. W., Roos, D. S., Striepen, B., Thompson, R. C., Ward, H. D., Van Voorhis, W. A., Xiao, L., Zhu, G., and Houpot, E. R. (2015) A review of the global burden, novel diagnostics, therapeutics, and vaccine targets for cryptosporidium. Lancet Infect Dis. 15 (1), 85–94.

(2) Current, W. L., and Reese, N. C. (1986) A comparison of endogenous development of three isolates of Cryptosporidium in suckling mice. J. Protozool. 33 (1), 98–108.

(3) Chappell, C. L., Okhuyen, P. C., Sterling, C. R., and Dupont, H. L. (1996) Cryptosporidium parvum: intensity of infection and oocyst excretion patterns in healthy volunteers. J. Infect. Dis. 173 (1), 232–6.

(4) Moore, S. R., Lima, N. L., Soares, A. M., Oria, R. B., Pinkerton, R. C., Barrett, L. J., Guerraant, R. L., and Lima, A. A. (2010) Prolonged episodes of acute diarrhea reduce growth and increase risk of persistent diarrhea in children. Gastroenterology 139 (4), 1156–64.

(5) Khäi, I. A., Treger, C., Rao, P. C., Blacker, B. F., Brown, A., Brewer, T. G., Colombara, D. V., De Hostos, E. L., Engmann, C., Guerraant, R. L., Haque, R., Houpot, E. R., Kang, G., Korpe, P. S., Kotloff, K. L., Lima, A. A. M., Petri, W. A. Jr., Platt-Mills, J. A., Sholtz, D. A., Forouzanfar, M. H., Hay, S. I., Reiner, R. C., Jr., and Mokdad, A. H. (2018) Mortality, morbidity, and long-term consequences associated with diarrhoea from Cryptosporidium infection in children younger than 5 years: a meta-analyses study. Lancet. Global health 6 (7), e758–e768.
Ferguson, L., Jimenez-Diaz, M. B., Junami, R. S., Lorimer, D. D., Love, M. S., Maher, S., Matthews, H., McNamara, C. W., Miller, P., O'Neill, S., Ojo, K. K., Osuna-Cabello, M., Pinto, E., Post, J., Riley, J., Rottmann, M., Sanz, L. M., Scullion, P., Sharma, A., Shepherd, S. M., Shishikura, Y., Simeons, F. R. C., Stebbins, E. E., Stojanovski, L., Straschil, U., Tamaki, F. K., Tamjar, J., Torrie, L. S., Vautaux, A., Witkowski, B., Wittlin, S., Yogavel, M., Zuccotto, F., Angulo-Barturen, I., Linden, R., Baum, J., Gamo, F. J., Maser, P., Kyle, D. E., Winzeler, E. A., Myler, P. J., Wyatt, P. G., Floyd, D., Matthews, D., Sharma, A., Striepen, B., Huston, C. D., Gray, D. W., Fairlamb, A. H., Pisiakow, A. V., Walpole, C., Read, K. D., Van Voorhis, W. C., and Gilbert, I. H. (2019) Lysyl-tRNA synthetase as a drug target in malaria and cryptosporidiosis. 

Commun. 10 (2019) Lysyl-tRNA synthetase as a drug target in malaria and cryptosporidiosis. 

Proc. Natl. Acad. Sci. U. S. A. 116 (14), 7015–7020. (29) Lunde, C. S., Stebbins, E. E., Junami, R. S., Hasan, M. M., Miller, P., Barlow, J., Freund, Y. R., Berry, P., Stefanakis, R., Gut, J., Rosenthal, P. J., Love, M. S., McNamara, C. W., Easom, E., Plattner, J. J., Jacobs, R. T., and Huston, C. D. (2019) Identification of a potent benzoxaborole drug candidate for treating cryptosporidiosis. Nat. Commun. 10 (1), 2816. (30) Swale, C., Bougdour, A., Gnaouri-David, A., Tottey, J., Georgeault, S., Laurent, F., Palencia, A., and Hakimi, M. A. (2019) Metal-captured inhibition of pre-mRNA processing activity by CPSF3 controls Cryptosporidium infection. Sci. Transl. Med. 11 (517), eaax7161. (31) Vinayak, S., Junami, R. S., Miller, P., Hasan, M. M., McLeod, B. I., Tandel, J., Stebbins, E. E., Teixeira, J. E., Borrel, J., Gonse, A., Zhang, M., Yu, X., Wernimont, A., Walpole, C., Eckley, S., Love, M. S., McNamara, C. W., Sharma, M., Sharma, A., Scherer, C. A., Kato, N., Schreiber, S. L., Mellilo, B., Striepen, B., Huston, C. D., and Comer, E. (2020) Bicyclic azetidines kill the diarrheal pathogen Cryptosporidium in mice by inhibiting parasite phenylalanyl-tRNA synthetase. Sci. Transl. Med. 12 (563), eaba8412. (32) Hasan, M. M., Stebbins, E. E., Choy, R. K. M., Gillespie, J. R., de Hostos, E. L., Miller, P., Mushtaq, A., Ranade, R. M., Teixeira, J. E., Verlinde, C. L. M. J., Sateriale, A., Zhang, Z., Osbourn, D. M., Griggs, D. W., Fan, E., Buckner, F. S., and Huston, C. D. (2021) Spontaneous selection of Cryptosporidium drug resistance in a calf model of infection. bioRxiv, 2021.01.04.425361. DOI: 10.1101/2021.01.04.425361. (33) Janes, J., Young, M. E., Chen, E., Rogers, N. H., Burgstaller-Muelbacher, S., Hughes, L. D., Love, M. S., Hull, M. V., Kuhen, K. L., Woods, A. J., Joseph, S. B., Petrasii, H. M., McNamara, C. W., Tremblay, M. S., Sür, A. L., Schultz, P. G., and Chappell, C. L., Okhuysen, P. C., Langer-Curry, R., Widmer, G., Akiyoshi, D. E., Tanriverdi, S., and Tzipori, S. (2006) Cryptosporidium hominis: experimental challenge of healthy adults with pre-existing anti-C. parvum serum immunoglobulin G. Am. J. Trop. Med. Hyg. 66 (3), 325–8. (34) Chappell, C. L., Okhuysen, P. C., Langer-Curry, R., Wang, C., Jakubowski, W., and Dupont, H. L. (1999) Virulence of three distinct Cryptosporidium parvum isolates for healthy adults. J. Infect. Dis. 180 (4), 1275–81. (35) Morada, M., Lee, S., Gunther-Cummins, L., Weiss, L. M., Chappell, C. L., Okhuysen, P. C., White, A. C., Jr., and Tzipori, S. (2010) Continuous culture of Cryptosporidium parvum isolates for healthy adults. Infect. Immun. 78 (5), 2170–8. (36) Akiyoshi, D. E., Widmer, G., Tzipori, S., and Yarlett, N. (2016) Continuous culture of Cryptosporidium parvum in healthy volunteers. Proc. Natl. Acad. Sci. U. S. A. 113 (1), 58–63. (37) Akiyoshi, D. E., Widmer, G., Tzipori, S., and Yarlett, N. (2016) Continuous culture of Cryptosporidium parvum in healthy volunteers. Proc. Natl. Acad. Sci. U. S. A. 113 (1), 58–63.
(55) Baldry, M. G. (1983) The bactericidal, fungicidal and sporidial properties of hydrogen peroxide and peracetic acid. J. Appl. Bacteriol. 54 (3), 417–23.

(56) Barbee, S. L., Weber, D. J., Sobsey, M. D., and Rutala, W. A. (1999) Inactivation of Cryptosporidium parvum oocyst infectivity by disinfection and sterilization processes. Gastrointest Endosc 49 (5), 605–11.

(57) Jaskiewicz, J. J., Sevenler, D., Swei, A. A., Widmer, G., Toner, M., Tzipori, S., and Sandlin, R. D. (2020) Cryopreservation of infectious Cryptosporidium parvum oocysts achieved through vitrification using high aspect ratio specimen containers. Sci. Rep. 10 (1), 11711.

(58) Jaskiewicz, J. J., Sandlin, R. D., Swei, A. A., Widmer, G., Toner, M., and Tzipori, S. (2018) Cryopreservation of infectious Cryptosporidium parvum oocysts. Nat. Commun. 9 (1), 2883.

(59) Nader, J. L., Mathers, T. C., Ward, B. J., Pachebat, J. A., Swain, M. T., Robinson, G., Chalmers, R. M., Hunter, P. R., van Oosterhout, C., and Tyler, K. M. (2019) Evolutionary genomics of anthroponosis in Cryptosporidium. Nat. Microbiol 4 (5), 826–836.

(60) Morgan-Ryan, U. M., Fall, A., Ward, L. A., Hijjawi, N., Sulaiman, I., Payer, R., Thompson, R. C., Olson, M., Lal, A., and Xiao, L. (2002) Cryptosporidium hominis n. sp. (Apicomplexa: Cryptosporidiidae) from Homo sapiens. J. Eukaryotic Microbiol. 49 (6), 433–40.

(61) Peng, M. M., Xiao, L., Freeman, A. R., Arrowood, M. J., Escalante, A. A., Weltman, A. C., Ong, C. S., Mac Kenzie, W. R., Lal, A. A., and Beard, C. B. (1997) Genetic polymorphism among Cryptosporidium parvum isolates: evidence of two distinct human transmission cycles. Emerging Infect. Dis. 3 (4), 567–73.

(62) Abrahamson, M. S., Templeton, T. J., Enomoto, S., Abrhahte, J. E., Zhu, G., Lancto, C. A., Deng, M., Liu, C., Widmer, G., Tzipori, S., Buck, G. A., Xu, P., Bankier, A. T., Dear, P. H., Konfortov, B. A., Spriggs, H. F., Iyer, L., Anantharaman, V., Aravind, L., and Kapur, V. (2004) Complete genome sequence of the apicomplexan, Cryptosporidium parvum. Science 304 (5669), 441–5.

(63) Xu, P., Widmer, G., Wang, Y., Ozaki, L. S., Alves, J. M., Serrano, M. G., Puia, D., Manque, P., Akiyoshi, D., Mackey, A. J., Pearson, W. R., Dear, P. H., Bankier, A. T., Peterson, D. L., Abrahamson, M. S., Kapur, V., Tzipori, S., and Buck, G. A. (2004) The genome of Cryptosporidium hominis. Nature 431 (7012), 1107–12.

(64) Carter, B. L., Chalmers, R. M., and Davies, A. P. (2020) Health sequelae of human cryptosporidiosis in industrialised countries: a systematic review. Parasites Vectors 13 (1), 443.

(65) Stiff, R. E., Davies, A. P., Mason, B. W., Hutchings, H. A., and Chalmers, R. M. (2017) Long-term health effects after resolution of acute Cryptosporidium parvum infection: a 1-year follow-up of outbreak-associated cases. J. Med. Microbiol. 66 (11), 1607–1611.

(66) Carter, B. L., Stiff, R. E., Elwin, K., Hutchings, H. A., Mason, B. W., Davies, A. P., and Chalmers, R. M. (2019) Health sequelae of human cryptosporidiosis—a 12-month prospective follow-up study. Eur. J. Clin. Microbiol. Infect. Dis. 38 (9), 1709–1717.

(67) Hunter, P. R., Hughes, S., Woodhouse, S., Nicholas, R., Syed, Q., Chalmers, R. M., Verlander, N. Q., and Goodacre, J. (2004) Health sequelae of human cryptosporidiosis in immunocompetent patients. Clin. Infect. Dis. 39 (4), 504–510.

(68) Sawant, M., Baydoun, M., Creusy, C., Chabe, M., Viscogliosi, E., Certad, G., and Benamrouz-Vanneste, S. (2020) Cryptosporidium and Colon Cancer: Cause or Consequence? Microorganisms 8 (11), 1665.

(69) Zhang, N., Yu, X., Zhang, H., Cui, L., Li, X., Zhang, X., Gong, P., Li, J., Li, Z., Wang, X., Li, X., Li, T., Liu, X., Yu, Y., and Zhang, X. (2020) Prevalence and Genotyping of Cryptosporidium parvum in Gastrointestinal Cancer Patients. J. Cancer 11 (11), 3334–3339.

(70) Lima, A. A., Moore, S. R., Barboza, M. S., Jr, Soares, A. M., Schleupner, M. A., Newman, R. D., Sears, C. L., Nataro, J. P., Fedorko, D. P., Wuhib, T., Schorling, J. B., and Guerrant, R. L. (2000) Persistent diarrhea signals a critical period of increased diarrhea burdens and nutritional shortfalls: a prospective cohort study among children in northeastern Brazil. J. Infect. Dis. 181 (5), 1643–51.